A genetic test could aid the identification of men with prostate cancer who are most likely to benefit from immunotherapy.
A study has discovered the first genetic marker that can distinguish between aggressive versus benign bone tumors.
A first-of-its-kind vaccine, termed AST-VAC2, has moved into a Phase I clinical trial for non-small cell lung cancer patients.
The prostate cancer test combines genetic variations linked to prostate cancer and identifies the 1% of men that are at high risk.
We have brought together our top takeaways from the five days of ASCO 2018.
A study presented at the American Society of Clinical Oncology Annual Meeting (ASCO, 1–5 June 2018, IL, USA) has revealed…
In a medical breakthrough, a new approach to immunotherapy has led to complete regression of breast cancer in a patient unresponsive to all other treatments.
Results of a randomized clinical trial, presented at ASCO 2018, highlight the benefit of preoperative chemoradiotherapy for patients with pancreatic cancer that can be treated with surgery.
Researchers have demonstrated that taking a high dose of esomeprazole (Nexium®) along with a low dose aspirin, for at least 7 years, can reduce the risk of develop a high-grade dyslplasia or esophageal cancer.